Get the Stockscreener App
3.90
1.02%
-0.04
Kalaris Therapeutics Inc stock is traded at $3.90, with a volume of 23,861.
It is down -1.02% in the last 24 hours and down -9.72% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$3.94
Open:
$3.91
24h Volume:
23,861
Relative Volume:
0.10
Market Cap:
$92.84M
Revenue:
-
Net Income/Loss:
$-44.10M
P/E Ratio:
-1.8249
EPS:
-2.1371
Net Cash Flow:
$-49.09M
1W Performance:
-3.23%
1M Performance:
-9.72%
6M Performance:
-57.05%
1Y Performance:
-16.31%
1-Day Range:
$3.82
$3.95
1-Week Range:
$3.82
$4.135
52-Week Range:
$3.03
$11.88
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
3.90 | 98.08M | 0 | -44.10M | -49.09M | -2.1371 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Initiated | Morgan Stanley | Overweight |
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Nov-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
View All
Kalaris Therapeutics Inc Stock (KLRS) Latest News
Kalaris (KLRS): Posts a 0.73% Gain to $4.15 on the Day; Range Check: the Price Remains Bounded by the Supplied Support and Resistance on the DayIV Rank - vinanet.vn
Amy O'leary Vandekop Net Worth (2026) - GuruFocus
Liisa Ann Bayko Net Worth (2026) - GuruFocus
Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Kalaris Therapeutics, Inc. (NASDAQ: KLRS) Share Price, KLRS Stock News, KLRS Share Price & Updates - Kalkine
KLRS Q1 2026 Earnings: Narrower-Than-Expected Loss Spurs 4.38% Share AdvanceEarnings Manipulation Risk - vinanet.vn
Kalaris Therapeutics Reports Q2 Financial Results, Advances Clinical Program - VisionMonday.com
Kalaris Therapeutics, Inc. 2Q 2026: Net loss $(11.5M), Diluted EPS $(0.48) — 10-Q Summary - TradingView
Kalaris Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Kalaris Therapeutics Q2 Results: EPS beats estimate, losses narrow 21% YoY - scanx.trade
Form 8K Kalaris Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
Kalaris Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results - MarketBeat
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Kalaris Therapeutics Reports Q2 2026 Results and Advances Phase 1b/2 TH103 Study for Neovascular AMD - Quiver Quantitative
Kalaris Reports Q2 2026: $11.5M Quarterly Net Loss; $93.5M Cash on Hand - TradingView
KLRS: TH103 clinical progress and strong cash position support operations into Q4 2027 - TradingView
Kalaris Reports $11.5 Million Q2 Net Loss and TH103 Updates - Quiver Quantitative
BRIEF-Kalaris Therapeutics Inc Q2 Operating Income USD -12.386 Million Vs. IBES Estimate USD -12.5 Million - TradingView
Kalaris Therapeutics (KLRS) Slides 2.9% to $4.07 as Biotech Sellers Test Key SupportWeak Sell Signals - vinanet.vn
Kalaris Therapeutics Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4%Here's What Happened - MarketBeat
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf - GlobeNewswire
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders - WBOC TV
KLRS Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesTangible Book Value - vinanet.vn
Kalaris Therapeutics (KLRS) Holds Gains Near $3.51 as Stock Consolidates Between Key LevelsValue Stock Ideas - dars.gov.et
KLRS Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentMargin Compression Risk - vinanet.vn
Kalaris Therapeutics (KLRS) Sees Modest Gain as Stock Holds Above SupportSign of Weakness - dars.gov.et
Kalaris Therapeutics Inc (KLRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kalaris Therapeutics Inc (KLRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kalaris Therapeutics Inc (KLRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kalaris Therapeutics Inc (KLRS) Cash Flow - TradingKey
Kalaris Therapeutics Inc (KLRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
KLRS Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Bottom Line Despite No RevenueNet Profit Margin - vinanet.vn
TradingKey - TradingKey
KLRS|Kalaris Therapeutics Inc|Price:3.730|Chg%:-0.190 - TradingKey
KLRS|Kalaris Therapeutics Inc|Price:4.120|Chg%:-0.050 - TradingKey
Kalaris Therapeutics Inc (KLRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kalaris Therapeutics (KLRS) Drops 3.7% as Stock Tests Key Support ZonePoint of Control - vinanet.vn
Kalaris appoints Liisa Bayko as CFO - MSN
Why is Kalaris Therapeutics stock gaining Friday? - MSN
Kalaris Therapeutics Appoints Liisa Bayko as New Chief Financial Officer - VisionMonday.com
Kalaris Therapeutics files Form 3 for CFO Liisa Ann Bayko - Bitget
Kalaris Therapeutics appoints Liisa Bayko as CFO By Investing.com - Investing.com Nigeria
Kalaris Therapeutics appoints Liisa Bayko as CFO - Investing.com
Kalaris Therapeutics stock falls despite naming new CFO By Investing.com - Investing.com South Africa
Kalaris Therapeutics Appoints Liisa Bayko as New CFO - Contract Pharma
Kalaris Therapeutics stock falls despite naming new CFO - Investing.com
Kalaris Therapeutics, Inc. Announces Appointment of Liisa Bayko to Chief Financial Officer, Effective July 20, 2026 - marketscreener.com
Kalaris Therapeutics Strengthens Financial Leadership With New CFO - TipRanks
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kalaris Therapeutics Inc Stock (KLRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hagen Brett R | Chief Accounting Officer |
Mar 20 '26 |
Sale |
6.72 |
1,915 |
12,869 |
0 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):